MedTrace Logo

Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)

NCT02840799 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2023-12-18

Study results available
· View outcomes & findings →

Summary

This trial seeks to assess if potassium nitrate (KNO3) therapy improves exercise capacity and oxygen uptake in heart failure patients with preserved ejection fraction (HFpEF).

Conditions

Interventions

DRUG

Potassium Nitrate (KNO3)

The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed.

DRUG

Potassium Chloride (KCl)

Potassium Chloride (KCl) is the matching placebo control drug in this trial.

Sponsors & Collaborators

Principal Investigators

  • Julio A Chirinos, MD, PhD · University of Pennsylvania

  • Payman Zamani, MD · University of Pennsylvania

  • Sanjiv Shah, MD · Northwestern University

  • Sujith Kuruvilla, MD · Corporal Michael J Crescenz Veterans Affairs Medical Center (VA)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2022-08-31
Completion
2022-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02840799 on ClinicalTrials.gov